Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Explore how advanced human cell models, particularly microphysiological systems (MPS), are revolutionizing pre-clinical safety assessment in pharmaceutical development through this 32-minute webinar presented by Dr. Natacha Bohin from AstraZeneca. Learn about the critical role of early safety liability detection in drug discovery and how three-dimensional cell culture systems better recapitulate human tissue architecture compared to traditional two-dimensional models. Discover AstraZeneca's innovative human bone marrow MPS models that maintain stem and progenitor cells while supporting differentiation into erythroid, myeloid, and megakaryocyte lineages, enabling the capture of lineage-specific hematotoxicity for both monotherapy and combination treatments. Understand how these advanced models inform candidate drug selection and guide oncology drug combination dosing and scheduling strategies. Examine the integration of MPS data with Quantitative Systems Toxicology modeling approaches to enhance clinical translation accuracy. Address the current challenges facing widespread adoption of advanced cell models in the pharmaceutical industry, including standardization issues, cost considerations, time requirements, and analytical limitations. Gain insights into opportunities for improving these models and driving their broader implementation across the industry. The presentation covers three key learning objectives: describing how advanced human cell models enhance pre-clinical to clinical translation, illustrating bone marrow MPS applications in hematotoxicity assessment, and discussing industry adoption challenges with proposed solutions for advancement.
